ClinicalTrials.gg
CompletedNCT00492557Updated Feb 17, 2012Results posted

Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 13vPnC + TIV in Pneumococcal Infections, sponsored by Pfizer. Completed. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,185
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
6th of 44
1,185 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
5th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 6th largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 5th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation of the lungs). As trivalent influenza vaccine (TIV) is frequently given to adults, it is important to show that both vaccines can safely be given together without affecting the immune response (body's ability to protect against disease).

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Pneumococcal Disease
  • Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Generally healthy male or female adults 65 years of age or older.
  • Available for the duration of the trial - approximately 2 months.
  • No previous vaccination with any pneumococcal vaccine.
  • No history of severe adverse reaction associated with a vaccine.
  • No allergy to egg proteins (eggs or egg products) and chicken proteins.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,185 participants (actual)

Study arms

  • Experimental
    13vPnC+TIV Followed by Placebo 1 month later

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    Placebo+TIV Followed by 13vPnC 1 month later

    Biological: 13vPnC + TIV

Interventions

  • Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.

  • Biological13vPnC + TIV

    Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.

06

What researchers measure

Primary outcomes

  1. TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)

    Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.

    Time frame: Baseline and 1 month after TIV vaccination

  2. 13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)

    IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: 1 month after 13vPnC vaccination

Other outcomes

  1. Percentage of Participants With Pre-specified Local Reactions

    Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (\> 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).

    Time frame: Days 1 through 14 after 13vPnC vaccination

  2. Percentage of Participants With Pre-specified Systemic Events

    Systemic events (Any fever \>= 38 degrees Celsius \[C\]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.

    Time frame: Days 1 through 14 after 13vPnC vaccination

07

Results

Posted Feb 17, 2012

Participant flow

Participant flow — Overall Study
Milestone13vPnC+TIV Followed by Placebo 1 Month LaterPlacebo+TIV Followed by 13vPnC 1 Month Later
Started580580
Vaccinated dose 1577575
Vaccinated dose 2560558
Completed556557
Not completed2423
Withdrew: Subject request1211
Withdrew: Protocol violation78
Withdrew: Other22
Withdrew: Death11
Withdrew: Adverse event10
Withdrew: Failed to return10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryTIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)

Percentage of participants achieving at least a 4-fold increase in the titer of the standard HAI for each influenza virus subtype (A/H1N1, A/H3N2, and B) were compared.

Time frame:
Baseline and 1 month after TIV vaccination
Reported as:
Number · Percentage of participants
TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)
Percentage of participants13vPnC+TIVPlacebo+TIV
Influenza virus subtype: A/H1N180.3 (76.7 to 83.5)78.6 (74.9 to 81.9)
Influenza virus subtype: A/H3N258.0 (53.7 to 62.2)62.6 (58.4 to 66.6)
Influenza virus subtype: B52.2 (47.9 to 56.4)54.0 (49.7 to 58.3)
Statistical analysis
  • 13vPnC+TIV vs Placebo+TIV · Percent difference: 1.7 · 95% CI -3.1 to 6.5
  • 13vPnC+TIV vs Placebo+TIV · Percent difference: -4.6 · 95% CI -10.4 to 1.3
  • 13vPnC+TIV vs Placebo+TIV · Percent difference: -1.8 · 95% CI -7.8 to 4.1
Primary13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)

IgG GMC as measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
1 month after 13vPnC vaccination
Reported as:
Geometric mean · mcg/mL
13vPnC Comparisons: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)
mcg/mL13vPnC+TIV13vPnC
Serotype 12.52 (2.07 to 3.06)3.20 (2.61 to 3.91)
Serotype 31.08 (0.94 to 1.24)1.15 (1.01 to 1.30)
Serotype 42.15 (1.79 to 2.60)3.24 (2.65 to 3.96)
Serotype 54.74 (4.08 to 5.50)6.90 (5.87 to 8.11)
Serotype 6A4.61 (4.00 to 5.31)6.10 (5.13 to 7.24)
Serotype 6B6.24 (5.27 to 7.39)6.43 (5.33 to 7.76)
Serotype 7F7.63 (6.50 to 8.96)9.04 (7.58 to 10.79)
Serotype 9V4.97 (4.19 to 5.91)6.21 (5.27 to 7.33)
Serotype 148.95 (7.33 to 10.95)12.44 (9.94 to 15.57)
Serotype 18C8.88 (7.55 to 10.45)11.07 (9.40 to 13.04)
Serotype 19A11.93 (10.23 to 13.92)17.10 (14.54 to 20.10)
Serotype 19F4.78 (4.00 to 5.71)7.39 (6.02 to 9.08)
Serotype 23F5.82 (4.74 to 7.14)6.11 (4.97 to 7.50)
Statistical analysis
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.79 · 95% CI 0.60 to 1.04CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.94 · 95% CI 0.78 to 1.13CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.66 · 95% CI 0.51 to 0.87CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.69 · 95% CI 0.55 to 0.86CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.76 · 95% CI 0.61 to 0.94CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.97 · 95% CI 0.75 to 1.25CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.84 · 95% CI 0.67 to 1.07CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.80 · 95% CI 0.63 to 1.02CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.72 · 95% CI 0.53 to 0.97CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.80 · 95% CI 0.64 to 1.01CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.70 · 95% CI 0.56 to 0.87CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.65 · 95% CI 0.49 to 0.85CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Ratio of gmcs: 0.95 · 95% CI 0.71 to 1.27CIs for the ratio were back transformations of the CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
Other pre-specifiedPercentage of Participants With Pre-specified Local Reactions

Local reactions were reported using an electronic diary. Pain was scaled as Any; Mild (awareness but easily tolerated); Moderate (discomfort enough to interfere with usual activity) and Severe (incapacitating the usual activity). Redness and swelling were scaled as Any; Mild (2.5 cm to 5.0 cm); Moderate (5.1 to 10.0 cm)and Severe (\> 10.0 cm). Limitation in arm movement were scaled as Any; Mild (some limitation); Moderate (unable to move above head but able to move above shoulder) and Severe (unable to move above shoulder).

Time frame:
Days 1 through 14 after 13vPnC vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-specified Local Reactions
percentage of participants13vPnC+TIV13vPnC
Redness: Any (n= 440, 432)16.6 (-0.4 to 9.0)12.3 (-0.4 to 9.0)
Redness: Mild (n= 438, 432)14.4 (0.3 to 9.1)9.7 (0.3 to 9.1)
Redness: Moderate (n= 433, 424)6.0 (-3.4 to 3.1)6.1 (-3.4 to 3.1)
Redness: Severe (n= 429, 420)0.7 (-1.8 to 1.2)1.0 (-1.8 to 1.2)
Swelling: Any (n= 441, 431)13.8 (-0.7 to 8.0)10.2 (-0.7 to 8.0)
Swelling: Mild (n= 440, 430)11.8 (-0.3 to 7.7)8.1 (-0.3 to 7.7)
Swelling: Moderate (n= 432, 423)4.2 (-3.7 to 2.1)5.0 (-3.7 to 2.1)
Swelling: Severe (n= 428, 420)0.2 (-0.7 to 1.3)0.0 (-0.7 to 1.3)
Pain: Any (n= 480, 470)40.0 (-9.7 to 3.0)43.4 (-9.7 to 3.0)
Pain: Mild (n= 470, 462)34.3 (-9.8 to 2.6)37.9 (-9.8 to 2.6)
Pain: Moderate (n= 447, 442)14.8 (-9.9 to 0.1)19.7 (-9.9 to 0.1)
Pain: Severe (n= 429, 421)1.4 (-3.4 to 0.8)2.6 (-3.4 to 0.8)
Limitation of arm movement: Any (n= 445, 432)13.9 (-5.6 to 3.8)14.8 (-5.6 to 3.8)
Limitation of arm movement: Mild (n= 444, 432)13.1 (-4.9 to 4.2)13.4 (-4.9 to 4.2)
Limitation of arm movement:Moderate (n= 430, 420)1.4 (-1.2 to 2.2)1.0 (-1.2 to 2.2)
Limitation of arm movement: Severe (n= 429, 420)1.9 (-1.4 to 2.4)1.4 (-1.4 to 2.4)
Any local reaction (n= 488, 470)46.9 (-6.0 to 6.7)46.6 (-6.0 to 6.7)
Other pre-specifiedPercentage of Participants With Pre-specified Systemic Events

Systemic events (Any fever \>= 38 degrees Celsius \[C\]), fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, any aggravated muscle pain, new joint pain or any aggravated joint pain. Participants may be presented in more than one category.

Time frame:
Days 1 through 14 after 13vPnC vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-specified Systemic Events
Percentage of participants13vPnC+TIV13vPnC
Fever >=38 degreesC but <38.5 degreesC (n=434,423)3.0 (-2.5 to 2.3)3.1 (-2.5 to 2.3)
Fever >=38.5 degreesC but <39 degreesC (n=430,421)1.4 (-1.2 to 2.2)1.0 (-1.2 to 2.2)
Fever >=39degreesC but <=40.0degreesC (n=428,420)0.0 (-0.9 to 0.9)0.0 (-0.9 to 0.9)
Fever >40.0 degrees C (n= 429, 422)1.4 (-0.8 to 2.4)0.7 (-0.8 to 2.4)
Fatigue (n= 476, 456)37.4 (2.8 to 14.9)28.5 (2.8 to 14.9)
Headache (n= 472, 449)32.6 (2.1 to 13.8)24.7 (2.1 to 13.8)
Chills (n= 443, 429)13.8 (0.4 to 9.0)9.1 (0.4 to 9.0)
Rash (n= 433, 427)6.9 (-3.3 to 3.6)6.8 (-3.3 to 3.6)
Vomiting (n= 432, 424)3.0 (-0.7 to 3.6)1.7 (-0.7 to 3.6)
Decreased appetite (n= 450, 434)16.9 (1.0 to 10.2)11.3 (1.0 to 10.2)
New muscle pain (n= 468, 448)26.9 (-2.2 to 9.1)23.4 (-2.2 to 9.1)
Any aggravated muscle pain (n= 454, 439)18.7 (-1.2 to 8.7)15.0 (-1.2 to 8.7)
New joint pain (n= 452, 435)16.2 (0.1 to 9.2)11.5 (0.1 to 9.2)
Any aggravated joint pain (n= 452, 428)15.7 (2.7 to 11.4)8.6 (2.7 to 11.4)
Any systemic event (n= 510, 488)60.2 (5.4 to 17.8)48.6 (5.4 to 17.8)
Post-hoc13vPnC Comparisons: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)

Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of a subset of participants using a microcolony OPA (mcOPA) assay.

Time frame:
1 month after 13vPnC vaccination
Reported as:
Geometric mean · Geometric mean titers
13vPnC Comparisons: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT)
Geometric mean titers13vPnC+TIV13vPnC
Serotype 1 (n= 256, 255)88 (71.1 to 108.3)95 (76.8 to 117.9)
Serotype 3 (n= 235, 237)46 (37.9 to 56.1)51 (41.7 to 61.7)
Serotype 4 (n= 247, 245)997 (766.3 to 1296.0)1486 (1174.7 to 1879.8)
Serotype 5 (n= 245, 234)124 (97.3 to 158.8)112 (85.1 to 146.3)
Serotype 6A (n= 250, 252)1220 (950.6 to 1566.7)1597 (1256.4 to 2030.3)
Serotype 6B (n= 259, 248)1564 (1239.4 to 1973.9)2017 (1564.8 to 2599.9)
Serotype 7F (n= 246, 248)607 (444.2 to 828.8)835 (619.9 to 1123.9)
Serotype 9V (n= 247, 242)477 (348.5 to 652.7)723 (528.1 to 988.9)
Serotype 14 (n= 247, 236)975 (781.6 to 1215.5)1088 (858.4 to 1379.1)
Serotype 18C (n= 250, 244)1158 (909.5 to 1475.1)1415 (1122.0 to 1785.8)
Serotype 19A (n= 251, 247)445 (365.1 to 542.1)539 (427.8 to 679.7)
Serotype 19F (n= 247, 242)378 (295.8 to 483.8)467 (360.7 to 605.1)
Serotype 23F (n= 252, 242)245 (180.2 to 332.4)295 (217.9 to 400.8)
Statistical analysis
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.9 · 95% CI 0.68 to 1.242-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.9 · 95% CI 0.69 to 1.202-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.7 · 95% CI 0.47 to 0.952-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 1.1 · 95% CI 0.77 to 1.602-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.54 to 1.082-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.55 to 1.092-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.7 · 95% CI 0.47 to 1.122-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.7 · 95% CI 0.42 to 1.032-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.9 · 95% CI 0.65 to 1.242-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.59 to 1.142-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.61 to 1.122-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.57 to 1.162-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.
  • 13vPnC+TIV vs 13vPnC · Gmt ratio: 0.8 · 95% CI 0.54 to 1.272-sided 95% CIs for the GMT ratio were calculated by back transformations of the 95% CIs based on the Student t distribution for the mean difference of the logarithmically transformed assay results.

Adverse events

Collected over AEs/SAEs recorded from signing of informed consent form to completion of study (Visit 3).Participants recorded in the e-diary their local reactions,systemic events & use of antipyretic & pain medication (Day 1-Day 14 after study vaccine administration).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC+TIV—4/576 (0.7%)307/576 (53.3%)
Placebo—8/559 (1.4%)194/559 (34.7%)
Placebo+TIV—0/575 (0%)256/575 (44.5%)
13vPnC—5/558 (0.9%)237/558 (42.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
Event13vPnC+TIVPlaceboPlacebo+TIV13vPnC
Cardiac failureCardiac disorders1/5762/5590/5751/558
Duodenal ulcer perforationGastrointestinal disorders0/5760/5590/5751/558
Gastrointestinal haemorrhageGastrointestinal disorders0/5760/5590/5751/558
PeritonitisGastrointestinal disorders0/5760/5590/5751/558
Sternal fractureInjury, poisoning and procedural complications0/5760/5590/5751/558
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5760/5590/5751/558
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5760/5590/5751/558
Angina pectorisCardiac disorders1/5761/5590/5750/558
Atrial fibrillationCardiac disorders0/5761/5590/5750/558
CholecystitisHepatobiliary disorders0/5761/5590/5750/558
Most frequent other events
Showing 10 of 173
Most frequent other events
Event13vPnC+TIVPlaceboPlacebo+TIV13vPnC
Pain (any)Skin and subcutaneous tissue disorders192/48040/41145/445204/470
Pain (mild)Skin and subcutaneous tissue disorders161/47033/40840/443175/462
FatigueGeneral disorders178/476120/434154/483130/456
HeadacheGeneral disorders154/472114/436139/468111/449
New muscle painGeneral disorders126/46847/41376/456105/448
Pain (moderate)Skin and subcutaneous tissue disorders66/44710/39714/43787/442
Any aggravated muscle painGeneral disorders85/45444/41063/44966/439
Decreased appetiteGeneral disorders76/45058/41566/45249/434
Redness (any)Skin and subcutaneous tissue disorders73/4406/39311/43353/432
New joint painGeneral disorders73/45245/40859/45150/435

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC+TIV Followed by Placebo 1 Month LaterPlacebo+TIV Followed by 13vPnC 1 Month LaterTotal
Mean72.1 ± 5.672.1 ± 5.572.1 ± 5.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC+TIV Followed by Placebo 1 Month LaterPlacebo+TIV Followed by 13vPnC 1 Month LaterTotal
Female289290579
Male287285572
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 4 years after primary completion. A results delay was requested in Jan 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 27, 2007
Start
Sep 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results delay requested
Jan 21, 2009
Results first posted
Feb 17, 2012
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00492557
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 27, 2007
Start date
Sep 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Feb 17, 2012
Last update
Feb 17, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion